 NEW YORK, May 05, 2022 GLOBE NEWSWIRE -- Cellectis the Company Euronext Growth: ALCLS - NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31st, 2022, on Thursday, May 12th, 2022, after the close of the US market. 